Abstract
We read with interest the paper by Coll et al. that reported a mortality rate of 27% in a large series of transplant recipients with concurrent COVID-19; with nosocomial acquisition in 13% of cases.1 Outside the pandemic setting, however, solid-organ-transplant (SOT) recipients are more likely to experience prolonged and severe illness from common respiratory-viral-infections (RVIs), and healthcare-associated-RVI (HA-RVI) is a significant issue. The impetus for implementation of aggressive infection-prevention measures against COVID-19 on transplant units may reduce HA-RVI as a positive consequence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
